Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers

Clinical trial NCT05205330 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05205330
Sponsor: Rottapharm Biotech
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Refractory Metastatic Colorectal Cancer Solid Tumor Metastatic Microsatellite-stable Colorectal Cancer Mismatch Repair Protein Proficient Metastatic GI Cancers Gastric Cancer

Start date: 2021-11-23
Primary completion: 2026-12-01
Enrollment: 107

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.